Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Biopharmaceutical Stock Soars on Positive Drug Update
11:22am, Wednesday, 23'rd Aug 2023
The shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) are soaring, after the biopharmaceutical concern identified the potential cause of an issue with its eye disorder treatment, Syfovre, which tre
Why Is Apellis Pharmaceuticals (APLS) Stock Up 23% Today?
08:28am, Wednesday, 23'rd Aug 2023
Apellis Pharmaceuticals (NASDAQ: APLS ) stock is on the rise Wednesday after the biopharmaceutical company announced an update on injection kits. The big news here is new guidelines for the use of it
Apellis Pharmaceuticals stock surges after investigation finds needles are potential cause of injection side effect
08:04am, Wednesday, 23'rd Aug 2023
Apellis Pharmaceuticals Inc. shares APLS, -2.26% jumped 30% premarket on Wednesday after the company identified a potential cause for a rare but serious side effect linked with its Syfovre injection f
Apellis Pharmaceuticals stock jumps on safety review update
07:52am, Wednesday, 23'rd Aug 2023
Apellis Pharmaceuticals Inc (NASDAQ:APLS) jumped some 30% in Wednesday's premarket after last night updating investors on an ongoing safety review of injection kits, used with SYFOVRE, its treatment f
3 Sorry Pharma Stocks to Sell in August Before It's Too Late
04:38pm, Tuesday, 22'nd Aug 2023
Pharmaceutical stocks can bring you from rags to riches — and back to rags again. The truth is the innovative sector can function similarly to a lottery.
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
07:43pm, Monday, 21'st Aug 2023
Biotech stocks may offer some of the most explosive opportunities on the market. For one, we have millions of baby boomers demanding better care.
Apellis (APLS) Focuses on Empaveli to Fuel Its Growth
10:55am, Tuesday, 15'th Aug 2023
Apellis' (APLS) first marketed product, Empaveli, continues to be the growth driver since its launch. However, Syfovre faces some safety concerns post promising takeoff.
Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin
11:21am, Monday, 07'th Aug 2023
Astellas Pharma won FDA approval for a rival to Apellis Pharmaceuticals' eye-disease treatment and APLS stock plunged Monday.
Apellis (APLS) Q2 Earnings Top, Syfovre Sales Boost Revenues
11:55am, Tuesday, 01'st Aug 2023
Apellis (APLS) reports better-than-expected second-quarter 2023 results. However, the stock falls 20% due to ambiguity surrounding Syfovre's safety profile.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates
09:38am, Monday, 31'st Jul 2023
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $1.35. This compares to loss of $1.46 per share a year ago.
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
09:00am, Monday, 24'th Jul 2023
WALTHAM, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host
Apellis (APLS) Plunges on Safety Issues With Eye Treatment
12:52pm, Wednesday, 19'th Jul 2023
Apellis (APLS) suffers a setback on reports of six events of retinal vasculitis (or inflammation) following treatment with Syfovre (pegcetacoplan injection).
Down -41.23% in 4 Weeks, Here's Why Apellis Pharmaceuticals, Inc. (APLS) Looks Ripe for a Turnaround
11:22am, Tuesday, 18'th Jul 2023
Apellis Pharmaceuticals, Inc. (APLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raisin
Apellis: Exercise Caution In Response To Safety Signal (Rating Downgrade)
10:08am, Tuesday, 18'th Jul 2023
Apellis Pharmaceuticals, Inc. shares dropped 37% following reports of eye inflammation cases related to its geographic atrophy treatment, Syfovre. The company reported six incidents of retinal vasculi
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
07:00am, Wednesday, 07'th Jun 2023
WALTHAM, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will par
